Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool

January 12, 2024 By The ASCO Post Staff

Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who may benefit from disease-specific therapies or enrollment in clinical trials (Abstract 901).

Related Content